Links to the Breadcrumb trail
- PMN business
Author of the article:
Content of the article
The US Centers for Disease Control and Prevention (CDC) released recommendations on Friday from its group of independent experts on the smallpox vaccine, which limits its use to people who work closely with viruses such as monkeypox.
The Jynneos vaccine, produced by Bavarian Nordic, will be available to certain healthcare professionals and laboratory staff at a time when monkeypox infections are spreading in Europe, the United States and beyond.
The vaccine was approved in the United States in 2019 to prevent smallpox and monkeypox in high-risk adults aged 18 and over.
Advertising 2
This ad is not yet loaded, but your article continues below.
Content of the article
CDC officials said earlier this week that they were in the process of releasing some doses of the Jynneos vaccine for people in contact with known monkeypox patients.
Officials said there were more than 100 million doses of an older smallpox vaccine called ACAM2000, produced by Emergent BioSolutions, which has significant side effects.
Smallpox is a mild viral infection that is endemic in some parts of Africa, but the recent outbreak in countries where the virus is not usually spread has raised concerns.
So far, there are about 300 confirmed or suspected cases in about 20 countries where the virus has not previously circulated. The World Health Organization has called for swift action by countries to curb the spread of monkeypox.
Advertising 3
This ad is not yet loaded, but your article continues below.
Content of the article
The CDC said its expert recommendations were intended for clinical laboratory staff performing diagnostic tests for orthopoxviruses such as smallpox and monkeypox, laboratory researchers doing viruses and healthcare professionals applying the ACAM2000 vaccine or caring for patients. infected with orthopoxviruses.
The publication of a vote by the CDC’s Advisory Committee on Immunization Practices last November formalized the recommendations.
Both ACAM2000 and Jynneos are available to prevent orthopoxvirus infections among at-risk individuals, the CDC said Friday. (Report by Manas Mishra and Amruta Handekar in Bengaluru; Edited by Krishna Chandra Eluri and Shailesh Kuber)
Share this article on your social network
Advertising
This ad is not yet loaded, but your article continues below.
Financial publications Top stories
Sign up to receive daily top stories from Financial Post, a division of Postmedia Network Inc.
By clicking the register button, you agree to receive the above newsletter from Postmedia Network Inc. You can unsubscribe at any time by clicking the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300
Thank you for registering!
Email is welcome. If you don’t see it, please check your junk folder.
The next issue of Financial Post Top Stories will be in your inbox soon.
There was a problem registering with you. Please, try again
Comments
Postmedia is committed to maintaining a lively but civic discussion forum and encourages all readers to share their views on our articles. It can take up to an hour to moderate comments before they appear on the site. Please keep your comments up to date and respectful. We have enabled email notifications – you will now receive an email if you receive a response to your comment, there is an update on the thread for comments you follow, or if a user you follow comments on a comment. Visit our Community Guidelines for more information and details on how to adjust your email settings.
Add Comment